COVID-19 Use Causes Tocilizumab Shortage.

Cancer discovery 2021 Dec 01

filter terms:

all
compound
show more »
show less «

Based on mounting evidence that tocilizumab improves survival in critically ill patients with COVID-19, the FDA granted it an emergency use authorization for COVID-19 treatment in June. Two months later, the agency added tocilizumab to its list of drug shortages, where it remains despite a slowly increasing supply. ©2021 American Association for Cancer Research.